title: [Comparison of therapeutic effects between transcatheter arterial chemoembolization and transcatheter arterial-portal venous double chemoembolization in treatment of moderate and advanced stages of primary liver carcinoma].
abstract: OBJECTIVE
  Many clinic data showed that it is difficult to control primary liver carcinoma (PLC) by transcatheter arterial chemoembolization (TACE) alone due to existence of double blood supply of liver by hepatic artery and portal vein. This study was designed to evaluate the efficacy of transcatheter arterial chemoembolization combined with portal venous chemoembolization (PVCE) in the treatment of moderate and advanced stages of PLC.
  
  
  METHODS
  Fifty-eight cases of moderate and advanced stages of PLC were treated with a combination of TACE and PVCE (TACE/PVCE group) and 118 patients with moderate and advanced stages of PLC were treated with TACE alone (TACE group).
  
  
  RESULTS
  (1)The total response rates were 86.2% in TACE+PVCE group and 69.5% in TACE group. The remarkable response rates were 31.0 % in TACE/PVCE group and 13.6% in TACE group (P< 0.05). (2)The half-year survival rates were 93.1% in TACE/PVCE group and 72.0% in TACE group (P< 0.05). The 1-year survival rates were 43.1% in TACE/PVCE group and 51.7% in TACE group. The 4-year survival rates were 6.9% in TACE/PVCE group and 5.1% in TACE group (P >0.05). (3) Side effects included fever, bellyache, white blood cell drop, hypohepatia, jaundice,and ascites. The degree of liver damage was positively associated with the amount of iodized oil.
  
  
  CONCLUSIONS
  The combination of TACE and PVCE appears to promote the short-term efficacy but not the long-term efficacy, compared with TACE alone for patients with moderate and advanced PLC.
authors.affiliation: Department of Diagnostic Imaging & Intervention, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China. wyaopan@mail.china.com
authors.forename: Yao-Pan
authors.initials: YP
authors.lastname: Wu
authors.forename: Wei-Zhang
authors.initials: WZ
authors.lastname: Zhang
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Rong-Ping
authors.initials: RP
authors.lastname: Guo
authors.forename: Chuan-Miao
authors.initials: CM
authors.lastname: Xie
authors.forename: Pei-Qiang
authors.initials: PQ
authors.lastname: Cai
mesh_terms: D016461:Chemoembolization, Therapeutic / Q000379:methods*; D006499:Hepatic Artery; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D011169:Portal Vein; D015996:Survival Rate